{"id":"06e82f4d-e2d5-4a09-a089-c752f2f22056","name":"EndoQuest Robotics","slug":"endoquest","description":"Houston-based endoluminal robotic surgery company. CEO Eduardo Fonseca. Endoluminal Surgical (ELS) System — flexible robot for scar-free procedures through natural orifices. PARADIGM Trial: FDA-approved final stage (Jan 2026), 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA). First robotic ESD by gastroenterologist in IDE trial (Oct 2025). Series D-2 co-led by Crescent Enterprises + Dr. Fred Moll (Intuitive Surgical co-founder). NVIDIA IGX Thor integration for AI vision. $176M total raised.","status":null,"founded":null,"hq":"Houston, TX","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.massdevice.com/endoquest-gets-fda-green-light-to-initiate-final-stage-of-surgical-robot-trial/","title":"EndoQuest FDA green light PARADIGM","sourceName":"MassDevice","dateAccessed":"2026-07-22"},{"url":"https://finance.yahoo.com/news/endoquest-robotics-secures-series-d-120000732.html","title":"EndoQuest Series D-2 Funding","sourceName":"Yahoo Finance/GlobeNewswire","dateAccessed":"2026-07-22"},{"url":"https://www.businesswire.com/news/home/20260112765182/en/EndoQuest-to-Bring-AI-Powered-Vision-and-Precision-to-Endoluminal-Robotic-Surgery-with-NVIDIA-IGX-Thor","title":"EndoQuest NVIDIA IGX Thor","sourceName":"BusinessWire","dateAccessed":"2026-07-22"}],"keyFacts":[{"label":"Product","value":"Endoluminal Surgical (ELS) System — flexible endoluminal robot"},{"label":"Trial","value":"PARADIGM — FDA IDE, 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA)"},{"label":"FDA Status","value":"Final stage approved (Jan 2026). First robotic ESD by gastroenterologist (Oct 2025)."},{"label":"Total Funding","value":"$176M (Series D-2, Crescent Enterprises + Dr. Fred Moll co-led)"},{"label":"Partnership","value":"NVIDIA IGX Thor integration for AI-powered vision"},{"label":"CEO","value":"Eduardo Fonseca"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-22T21:32:37.672Z","updatedAt":"2026-07-22T23:21:51.050Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/endoquest","url":"https://registry.deploy.report/companies/endoquest","name":"EndoQuest Robotics","description":"Houston-based endoluminal robotic surgery company. CEO Eduardo Fonseca. Endoluminal Surgical (ELS) System — flexible robot for scar-free procedures through natural orifices. PARADIGM Trial: FDA-approved final stage (Jan 2026), 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA). First robotic ESD by gastroenterologist in IDE trial (Oct 2025). Series D-2 co-led by Crescent Enterprises + Dr. Fred Moll (Intuitive Surgical co-founder). NVIDIA IGX Thor integration for AI vision. $176M total raised.","identifier":"06e82f4d-e2d5-4a09-a089-c752f2f22056","address":"Houston, TX","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":3,"primary_source_types":[]}}}